Back

Circulating levels of amyloid-beta (1-40) peptide associate with cardiometabolic traits and risk for metabolic dysfunction-associated steatotic liver disease

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Liver metabolism and heart disease Metabolic Syndrome, Insulin, Insulin Resistance ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Evmorfia Aivalioti

National & Kapodistrian University of Athens Medical School, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Serum lipid profiles and uptake of lipid-lowering therapy in patients with premature atherosclerotic cardiovascular disease (ASCVD) in comparison to older patients with ASCVD
Professor T. Tan (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Angioprotein-like 3 and atheroma progression in statin-treated type 2 diabetic patients with coronary artery disease: the pre-specified analysis from the OPTIMAL randomized controlled trial.
Doctor S. Kitahara (Kashiwa, JP)
Abstract Slides Video
Presentation thumbnail
PCSK9 inhibitors in HIV patients with dyslipidemia
Doctor S. Datla (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
The effect of 6-month treatment with coenzyme Q10 on endothelial, vascular and myocardial function in patients with nonalcoholic fatty liver disease.
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The association of steatotic liver disease with recurrent ischemic events in patients with chronic coronary syndrome: a multicenter cohort study
Doctor G. Zeng (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Liver metabolism and heart disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Amyloid beta, a marker of vascular aging and cardiovascular disease, is associated with accelerated progression of renal dysfunction
thumbnail
Congress Presentation
Circulating Amyloid beta 1-40 is independently associated with statin treatment and LDL cholesterol reduction: a prospective cohort study
thumbnail
Congress Presentation
Plasma levels of amyloid beta 1-40 are associated with ultrasonographic morphological characteristics related with carotid plaque vulnerability in individuals without cardiovascular disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources